Literature DB >> 16801437

Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

Todd A Davies1, Wenchi Shang, Karen Bush.   

Abstract

The activities of ceftobiprole and other beta-lactams were examined with 30 Streptococcus pneumoniae isolates containing multiple pbp1a, pbp2b, and pbp2x mutations. The highest ceftobiprole MIC was 1 microg/ml, while the comparator MICs were 16 to 64 microg/ml. Fifty percent inhibitory concentrations for penicillin-binding protein 2x were 0.5 microg/ml (ceftobiprole) and 4 microg/ml (ceftriaxone) in a penicillin- and ceftriaxone-resistant isolate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801437      PMCID: PMC1489808          DOI: 10.1128/AAC.00238-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

Authors:  M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Authors:  Ronald N Jones; Lalitagauri M Deshpande; Alan H Mutnick; Douglas J Biedenbach
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

4.  Resistance issues and community-acquired respiratory infections.

Authors:  Daniel F Sahm
Journal:  Clin Cornerstone       Date:  2003

5.  Pneumococcal beta-lactam resistance due to a conformational change in penicillin-binding protein 2x.

Authors:  Raphaël Carapito; Laurent Chesnel; Thierry Vernet; André Zapun
Journal:  J Biol Chem       Date:  2005-11-22       Impact factor: 5.157

6.  Alterations in penicillin-binding protein 2B from penicillin-resistant wild-type strains of Streptococcus pneumoniae.

Authors:  A M Smith; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

7.  Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci.

Authors:  Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters.

Authors:  R Zbinden; V Pünter; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae.

Authors:  Kimberly A Nichol; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  G Laible; B G Spratt; R Hakenbeck
Journal:  Mol Microbiol       Date:  1991-08       Impact factor: 3.501

View more
  10 in total

1.  Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.

Authors:  Cesar A Arias; Kavindra V Singh; Diana Panesso; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

2.  In vitro activity of ceftobiprole and seven other antimicrobial agents against invasive Streptococcus pneumoniae isolates in Spain.

Authors:  E Ríos Dueñas; I Rodríguez-Avial; J J Picazo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-26       Impact factor: 3.267

3.  A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes.

Authors:  Ritu Banerjee; Michael Gretes; Christopher Harlem; Li Basuino; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

4.  Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.

Authors:  Todd A Davies; Wenping He; Karen Bush; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

5.  Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Authors:  Todd A Davies; Malcolm G P Page; Wenchi Shang; Ted Andrew; Malgosia Kania; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

6.  Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

Authors:  Anne Marie Queenan; Wenchi Shang; Malgosia Kania; Malcolm G P Page; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

7.  A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.

Authors:  Samir S Awad; Alejandro H Rodriguez; Yin-Ching Chuang; Zsuszanna Marjanek; Alex J Pareigis; Gilmar Reis; Thomas W L Scheeren; Alejandro S Sánchez; Xin Zhou; Mikaël Saulay; Marc Engelhardt
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

8.  Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.

Authors:  César Bustos; Jose L Del Pozo
Journal:  Infect Drug Resist       Date:  2010-04-22       Impact factor: 4.003

9.  In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens.

Authors:  K M Kumar; P Anitha; V Sivasakthi; Susmita Bag; P Lavanya; Anand Anbarasu; Sudha Ramaiah
Journal:  3 Biotech       Date:  2013-06-11       Impact factor: 2.406

Review 10.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.